| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 34 | 2022 | 744 | 2.890 |
Why?
|
| Endometrial Neoplasms | 16 | 2018 | 193 | 1.700 |
Why?
|
| Peritoneal Neoplasms | 11 | 2016 | 177 | 1.400 |
Why?
|
| Fallopian Tube Neoplasms | 7 | 2016 | 35 | 0.990 |
Why?
|
| Uterine Neoplasms | 5 | 2019 | 227 | 0.860 |
Why?
|
| Genital Neoplasms, Female | 4 | 2016 | 107 | 0.760 |
Why?
|
| MAP Kinase Kinase 4 | 5 | 2012 | 67 | 0.740 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2016 | 2438 | 0.720 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 74 | 0.680 |
Why?
|
| Intestinal Obstruction | 1 | 2019 | 87 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2019 | 1313 | 0.550 |
Why?
|
| Female | 66 | 2022 | 44546 | 0.460 |
Why?
|
| Neoplasm Metastasis | 12 | 2019 | 1056 | 0.450 |
Why?
|
| Omentum | 7 | 2018 | 71 | 0.440 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 20 | 0.430 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2012 | 150 | 0.410 |
Why?
|
| Tamoxifen | 1 | 2012 | 168 | 0.400 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2018 | 43 | 0.400 |
Why?
|
| MAP Kinase Signaling System | 5 | 2018 | 192 | 0.390 |
Why?
|
| Aged, 80 and over | 22 | 2022 | 6513 | 0.380 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2016 | 45 | 0.370 |
Why?
|
| Middle Aged | 38 | 2022 | 25035 | 0.360 |
Why?
|
| Aged | 35 | 2022 | 18421 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 2012 | 275 | 0.340 |
Why?
|
| Biomarkers, Tumor | 5 | 2014 | 1464 | 0.340 |
Why?
|
| Ovariectomy | 4 | 2014 | 81 | 0.330 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2019 | 36 | 0.330 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2008 | 12 | 0.320 |
Why?
|
| Epithelial Cells | 4 | 2017 | 669 | 0.320 |
Why?
|
| Humans | 68 | 2022 | 86656 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 101 | 0.320 |
Why?
|
| Proteomics | 2 | 2019 | 211 | 0.300 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 11 | 0.290 |
Why?
|
| Adult | 32 | 2022 | 25656 | 0.290 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 2006 | 12 | 0.280 |
Why?
|
| Fallopian Tubes | 2 | 2017 | 41 | 0.280 |
Why?
|
| Chylous Ascites | 1 | 2005 | 9 | 0.270 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2005 | 43 | 0.270 |
Why?
|
| Sarcoma | 2 | 2006 | 215 | 0.260 |
Why?
|
| Teratoma | 1 | 2005 | 50 | 0.260 |
Why?
|
| Hyperlipidemias | 2 | 2016 | 95 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 8 | 2016 | 1041 | 0.260 |
Why?
|
| Disease-Free Survival | 9 | 2015 | 1204 | 0.240 |
Why?
|
| Adipocytes | 2 | 2018 | 155 | 0.240 |
Why?
|
| Cisplatin | 9 | 2016 | 612 | 0.230 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 134 | 0.230 |
Why?
|
| Paclitaxel | 5 | 2012 | 460 | 0.230 |
Why?
|
| Adenocarcinoma, Clear Cell | 6 | 2012 | 62 | 0.220 |
Why?
|
| Retrospective Studies | 13 | 2019 | 8495 | 0.220 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 357 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 157 | 0.210 |
Why?
|
| Radiotherapy, Conformal | 4 | 2003 | 83 | 0.210 |
Why?
|
| Mice, Nude | 9 | 2018 | 790 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 378 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 10 | 2014 | 551 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2022 | 85 | 0.190 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 2426 | 0.190 |
Why?
|
| Sexual Behavior | 2 | 2015 | 302 | 0.180 |
Why?
|
| Hysterectomy | 8 | 2018 | 146 | 0.180 |
Why?
|
| Glycolysis | 2 | 2018 | 129 | 0.180 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2019 | 6 | 0.180 |
Why?
|
| Infusions, Intravenous | 5 | 2012 | 429 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 930 | 0.170 |
Why?
|
| Neoplasm Staging | 12 | 2012 | 1938 | 0.170 |
Why?
|
| Mice | 15 | 2018 | 11356 | 0.170 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 547 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1197 | 0.160 |
Why?
|
| Prognosis | 8 | 2019 | 3680 | 0.160 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 1208 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2017 | 2768 | 0.160 |
Why?
|
| Glycogen | 1 | 2018 | 59 | 0.160 |
Why?
|
| CD36 Antigens | 1 | 2018 | 13 | 0.160 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 52 | 0.160 |
Why?
|
| Coculture Techniques | 5 | 2018 | 164 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 592 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2011 | 199 | 0.150 |
Why?
|
| Combined Modality Therapy | 7 | 2006 | 1686 | 0.150 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 1753 | 0.150 |
Why?
|
| Carboplatin | 3 | 2012 | 286 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 325 | 0.140 |
Why?
|
| Cell Adhesion | 7 | 2014 | 420 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2004 | 292 | 0.140 |
Why?
|
| Caryophyllaceae | 1 | 2005 | 2 | 0.130 |
Why?
|
| Basidiomycota | 1 | 2005 | 10 | 0.130 |
Why?
|
| Cadherins | 2 | 2008 | 151 | 0.130 |
Why?
|
| Siderophores | 1 | 2005 | 22 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2019 | 7998 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 200 | 0.130 |
Why?
|
| Nanomedicine | 1 | 2015 | 14 | 0.130 |
Why?
|
| Animals | 17 | 2018 | 26590 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 153 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 15 | 0.130 |
Why?
|
| Polymers | 1 | 2016 | 202 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 178 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2016 | 157 | 0.120 |
Why?
|
| Pelvic Neoplasms | 3 | 2004 | 45 | 0.120 |
Why?
|
| Vinblastine | 2 | 2004 | 108 | 0.120 |
Why?
|
| Fibronectins | 1 | 2014 | 93 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 219 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 294 | 0.120 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2013 | 18 | 0.120 |
Why?
|
| Piperazines | 1 | 2005 | 272 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 853 | 0.110 |
Why?
|
| Neoplasm Transplantation | 3 | 2011 | 391 | 0.110 |
Why?
|
| Infusions, Parenteral | 2 | 2011 | 50 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 44 | 0.110 |
Why?
|
| Adenocarcinoma | 5 | 2004 | 1169 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 124 | 0.110 |
Why?
|
| Ustilago | 1 | 2002 | 5 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2012 | 1538 | 0.100 |
Why?
|
| Ascites | 1 | 2011 | 56 | 0.100 |
Why?
|
| Cystadenocarcinoma, Papillary | 4 | 2004 | 9 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2012 | 140 | 0.100 |
Why?
|
| Disease Progression | 4 | 2019 | 1532 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 170 | 0.100 |
Why?
|
| Anoikis | 1 | 2011 | 7 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2012 | 3642 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 311 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 81 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 182 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 861 | 0.100 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2010 | 21 | 0.100 |
Why?
|
| Anilides | 1 | 2011 | 47 | 0.100 |
Why?
|
| DNA Transposable Elements | 1 | 2002 | 169 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 232 | 0.100 |
Why?
|
| Viral Tail Proteins | 1 | 2010 | 2 | 0.090 |
Why?
|
| Quinolines | 1 | 2011 | 95 | 0.090 |
Why?
|
| Bacteriophage mu | 1 | 2010 | 17 | 0.090 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 84 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 458 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2016 | 4214 | 0.090 |
Why?
|
| Metformin | 1 | 2012 | 128 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 17 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 301 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 557 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 407 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 153 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2010 | 154 | 0.090 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2009 | 17 | 0.090 |
Why?
|
| Mutation | 6 | 2017 | 3968 | 0.090 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 2360 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 2903 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 378 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 79 | 0.080 |
Why?
|
| Integrin alpha5 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 24 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1384 | 0.080 |
Why?
|
| Fibroblasts | 2 | 2009 | 729 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2003 | 468 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1015 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 74 | 0.080 |
Why?
|
| Coagulation Protein Disorders | 1 | 2007 | 2 | 0.080 |
Why?
|
| Vaginitis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Immediate-Early Proteins | 1 | 2009 | 164 | 0.080 |
Why?
|
| Brachytherapy | 5 | 2012 | 119 | 0.080 |
Why?
|
| Plasminogen | 1 | 2007 | 41 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2009 | 326 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1579 | 0.080 |
Why?
|
| Bevacizumab | 3 | 2013 | 281 | 0.080 |
Why?
|
| Apoptosis | 4 | 2010 | 1683 | 0.080 |
Why?
|
| Escherichia coli | 1 | 2010 | 597 | 0.070 |
Why?
|
| Neoplasms | 2 | 2015 | 2898 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 28 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2009 | 352 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 79 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 1375 | 0.070 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2019 | 2819 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 79 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2004 | 295 | 0.070 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2006 | 41 | 0.070 |
Why?
|
| Cell Division | 2 | 2008 | 696 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2006 | 252 | 0.070 |
Why?
|
| Clitoris | 1 | 2005 | 4 | 0.070 |
Why?
|
| Carcinoma | 1 | 2009 | 436 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1077 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2008 | 279 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2006 | 506 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2005 | 32 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2006 | 173 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2018 | 715 | 0.060 |
Why?
|
| Chicago | 4 | 2016 | 1380 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 363 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2006 | 1565 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2006 | 435 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2005 | 67 | 0.060 |
Why?
|
| Physical Therapy Modalities | 1 | 2005 | 84 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2019 | 628 | 0.060 |
Why?
|
| Bleomycin | 1 | 2004 | 98 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2012 | 782 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1621 | 0.060 |
Why?
|
| Etoposide | 1 | 2004 | 196 | 0.060 |
Why?
|
| Cell Cycle | 3 | 2011 | 502 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 299 | 0.060 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 276 | 0.060 |
Why?
|
| Blood | 1 | 2002 | 69 | 0.060 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2002 | 6 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2006 | 448 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2006 | 403 | 0.050 |
Why?
|
| Young Adult | 4 | 2018 | 5980 | 0.050 |
Why?
|
| CA-125 Antigen | 2 | 2014 | 22 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2001 | 45 | 0.050 |
Why?
|
| Cell Movement | 2 | 2018 | 758 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2002 | 692 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2014 | 3243 | 0.050 |
Why?
|
| Lymphatic Metastasis | 4 | 2003 | 486 | 0.050 |
Why?
|
| Vaginal Neoplasms | 3 | 2007 | 83 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 388 | 0.040 |
Why?
|
| Quality of Life | 2 | 2022 | 1585 | 0.040 |
Why?
|
| Time Factors | 4 | 2012 | 5211 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 9 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 15 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 579 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2011 | 751 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2012 | 1981 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2006 | 468 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2006 | 1196 | 0.040 |
Why?
|
| Niacinamide | 1 | 2019 | 116 | 0.040 |
Why?
|
| Cell Death | 2 | 2011 | 256 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2018 | 57 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 1864 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 879 | 0.040 |
Why?
|
| Curettage | 1 | 2018 | 12 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2018 | 33 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 23 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2018 | 30 | 0.040 |
Why?
|
| Life Tables | 3 | 2003 | 48 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 52 | 0.040 |
Why?
|
| Integrin alpha5beta1 | 2 | 2008 | 13 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2012 | 226 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2011 | 270 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2008 | 83 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2009 | 188 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1961 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 311 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2003 | 176 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 91 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 916 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2231 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2016 | 79 | 0.030 |
Why?
|
| Endosomes | 1 | 2016 | 75 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 290 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 156 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 172 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Nanostructures | 1 | 2016 | 77 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2016 | 188 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 171 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 418 | 0.030 |
Why?
|
| Plant Diseases | 1 | 2005 | 75 | 0.030 |
Why?
|
| Lovastatin | 1 | 2014 | 29 | 0.030 |
Why?
|
| Sexuality | 1 | 2015 | 40 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 2062 | 0.030 |
Why?
|
| Integrins | 1 | 2014 | 76 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1163 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Inhibins | 1 | 2013 | 37 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 251 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 160 | 0.030 |
Why?
|
| Carcinoma, Adenosquamous | 2 | 2004 | 12 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 192 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 288 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 629 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2380 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 102 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 267 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 35 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1996 | 696 | 0.030 |
Why?
|
| Taxoids | 1 | 2012 | 129 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 328 | 0.030 |
Why?
|
| ras Proteins | 1 | 2012 | 128 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 154 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 26 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1540 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 138 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 70 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 242 | 0.030 |
Why?
|
| Meiosis | 1 | 2002 | 80 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1137 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 2004 | 321 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1188 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 720 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Models, Biological | 2 | 2008 | 1749 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 2010 | 17 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 197 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 8984 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 289 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1169 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 689 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 684 | 0.020 |
Why?
|
| Patient Safety | 1 | 2011 | 211 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 645 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 226 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 218 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 165 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cattle | 1 | 2009 | 376 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 736 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1106 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 125 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 10 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 31 | 0.020 |
Why?
|
| Keratins | 1 | 2007 | 63 | 0.020 |
Why?
|
| Vimentin | 1 | 2007 | 44 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 158 | 0.020 |
Why?
|
| Transgenes | 1 | 2008 | 180 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1824 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2206 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 589 | 0.020 |
Why?
|
| Femur Head | 1 | 2006 | 8 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 25 | 0.020 |
Why?
|
| Ilium | 1 | 2006 | 18 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 65 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 896 | 0.020 |
Why?
|
| Sacrum | 1 | 2006 | 40 | 0.020 |
Why?
|
| Peroxidases | 1 | 2006 | 34 | 0.020 |
Why?
|
| Homeostasis | 1 | 2008 | 409 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 426 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 95 | 0.020 |
Why?
|
| beta Catenin | 1 | 2007 | 251 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 429 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2271 | 0.020 |
Why?
|
| Neutropenia | 1 | 2006 | 215 | 0.020 |
Why?
|
| Orgasm | 1 | 2005 | 9 | 0.020 |
Why?
|
| Suction | 1 | 2005 | 35 | 0.020 |
Why?
|
| Anemia | 1 | 2006 | 128 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2005 | 48 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2006 | 183 | 0.020 |
Why?
|
| Cell Survival | 1 | 2007 | 969 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1376 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2006 | 250 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2006 | 911 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5420 | 0.010 |
Why?
|
| Protein Folding | 1 | 2006 | 282 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 2003 | 40 | 0.010 |
Why?
|
| Cystadenocarcinoma | 1 | 2003 | 12 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1564 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2003 | 39 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 1718 | 0.010 |
Why?
|
| COP9 Signalosome Complex | 1 | 2002 | 1 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 36 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 30 | 0.010 |
Why?
|
| Rectum | 1 | 2003 | 146 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 188 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 100 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2006 | 434 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 286 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2003 | 156 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 100 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 840 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 860 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2003 | 246 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2003 | 302 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 2262 | 0.010 |
Why?
|
| Pelvis | 1 | 2001 | 95 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 379 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 811 | 0.010 |
Why?
|
| Risk | 1 | 2001 | 674 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 1996 | 30 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 1996 | 34 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1996 | 65 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 157 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 1996 | 80 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1458 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 3047 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 3613 | 0.010 |
Why?
|
| Pedigree | 1 | 1996 | 966 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2587 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 3030 | 0.010 |
Why?
|
| Liver | 1 | 1996 | 1228 | 0.010 |
Why?
|
| Child | 1 | 2002 | 6928 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 3992 | 0.010 |
Why?
|
| Male | 2 | 2002 | 40983 | 0.000 |
Why?
|